NCI Urges full Disclosure of Cigarette Contents

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 11
Volume 5
Issue 11

BETHESDA, Md-The National Cancer Institute is urging the Federal Trade Commission (FTC) to replace its current cigarette testing protocol with one that provides the full range of tar, nicotine and carbon monoxide yields in individual cigarette brands.

BETHESDA, Md—The National Cancer Institute is urging the Federal Trade Commission (FTC) to replace its current cigarette testing protocol with one that provides the full range of tar, nicotine and carbon monoxide yields in individual cigarette brands.

The NCI's newest monograph in its series on Smoking and Tobacco Control contains the findings and recommendations of an expert committee that addressed the need for changes in the FTC's cigarette-testing method. The committee also recommended the following:

A public education campaign must accompany the new testing approach to make smokers aware that an individual's exposure depends on how a cigarette is smoked and that the benefits of switching to lower-yield cigarettes are small compared to quitting.

  • A simple, graphic representation of tar, nicotine, and carbon monoxide levels should appear on each pack sold and in all advertisements.
  • Other constituents in cigarettes should be listed on each pack and in all advertising, with each constituent classified by its toxic effects.
  • Terms such as "light" and "ultra light" represent health claims and should be regulated by the federal government.
  • Cigarette testing information should be available to the public, since it is useless unless smokers have access to it.
  • Questions about the purpose, methodology, and utility of the FTC's testing protocol are complex medical and scientific issues, and require the on-going involvement of federal health agencies.

Single copies of the monograph, "The FTC Cigarette Test Method for Determining Tar, Nicotine, and Carbon Monoxide Yields of US Cigarettes—Report of the NCI Expert Committee," are available from NCI at 1-800-422-6237.

Recent Videos
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
2 experts are featured in this series.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Related Content